Shamburg News · 8-K filed Nov 10, 2026, 4:50 PM EST

Gossamer Bio Reports Third Quarter 2026 Results and Submits Seralutinib NDA to FDA

GOSS · Gossamer Bio, Inc.

  • Earnings
  • Reg FD disclosure
  • Other event
  • Materiality: high

Gossamer Bio, Inc. reported third quarter 2026 results, with revenue from contracts with collaborators of $38.4 million and a net loss of $48.1 million, or $7.36 per share, for the quarter ended September 30, 2026. The company stated it submitted a New Drug Application for seralutinib in PAH to the FDA in September 2026 and completed a 1-for-80 reverse stock split that month. Cash, cash equivalents and marketable securities totaled $51.2 million as of September 30, 2026.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001728117-26-000116.

Written from the filing by Shamburg Markets. Figures are as reported by the company.